CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.67B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.79: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.67BUSDvs all stocks (USD)
Revenue (TTM)
204.73MUSDvs all stocks (USD)
Profit Margin
-51.07%vs Biotechnology peers
Beta
0.6500xvs all stocks
52-Week Change
204.20%vs all stocks
Market Capitalization
2.67BUSDvs all stocks (USD)
Enterprise Value
1.37BUSDvs all stocks (USD)
Forward P/E
-78.92xvs Biotechnology peers
Price to Sales (TTM)
13.04xvs Biotechnology peers
Price to Book (MRQ)
5.05xvs Biotechnology peers
Enterprise to Revenue
6.71xvs Biotechnology peers
Enterprise to EBITDA
-36.15xvs Biotechnology peers
Gross Margin
51.19%vs Biotechnology peers
Profit Margin
-51.07%vs Biotechnology peers
Operating Margin
1.09%vs Biotechnology peers
Return on Assets (TTM)
-6.59%vs Biotechnology peers
Return on Equity (TTM)
-40.98%vs Biotechnology peers
Revenue (TTM)
204.73MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.41USDUpdated Jul 19, 2026Quarterly Revenue Growth
40.50%vs Biotechnology peers
Gross Profit (TTM)
61.67MUSDvs all stocks (USD)
EBITDA (TTM)
-38.02MUSDvs all stocks (USD)
Net Income (TTM)
-104.56MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
40.53%vs Biotechnology peers
Operating Cash Flow (TTM)
-39.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-11.33MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
160.33MUSDFY2025 · Dec 31, 2025Revenue
185.74MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
151.75MUSDFY2025 · Dec 31, 2025Gross Profit
33.99MUSDFY2025 · Dec 31, 2025Operating Income
-128.53MUSDvs all stocks (USD)
Pre-tax Income
-234.97MUSDFY2025 · Dec 31, 2025Income Tax Expense
-4.21MUSDFY2025 · Dec 31, 2025Net Income
-230.76MUSDFY2025 · Dec 31, 2025EBIT
-207.98MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-60.77MUSDFY2025 · Dec 31, 2025Research & Development
17.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
145.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.44MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.99MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-230.76MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
99.99MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-139.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
-151.59MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
216.89MUSDFY2025 · Dec 31, 2025Interest Paid
24.98MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-230.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
60.47MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
4.06MUSDFY2025 · Dec 31, 2025Stock-based Compensation
30.17MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.87MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.82MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-7.35MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.45MUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.41MUSDFY2025 · Dec 31, 2025Net Acquisitions
-18.99MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-31.41MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-5.44MUSDFY2025 · Dec 31, 2025Other Financing Charges
-11.06MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-16.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
147.50MSharesUpdated Jul 19, 2026Float Shares
101.17MSharesUpdated Jul 19, 2026Shares Short
8.81MSharesUpdated Jul 19, 2026Short Ratio
2.62daysvs all stocks
Short % of Shares Outstanding
7.09%vs all stocks
% Held by Insiders
13.80%vs all stocks
% Held by Institutions
88.60%vs all stocks
Total Cash (MRQ)
165.92MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.13USDUpdated Jul 19, 2026Total Debt (MRQ)
315.03MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.8536xvs Biotechnology peers
Current Ratio (MRQ)
5.91xvs Biotechnology peers
Book Value per Share (MRQ)
1.43USDUpdated Jul 19, 2026Total Assets
770.58MUSDvs all stocks (USD)
Total Current Assets
296.25MUSDFY2025 · Dec 31, 2025Total Liabilities
397.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
474.33MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
352.95MUSDFY2025 · Dec 31, 2025Total Current Liabilities
44.92MUSDFY2025 · Dec 31, 2025Cash
216.89MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
216.89MUSDFY2025 · Dec 31, 2025Accounts Receivable
25.50MUSDFY2025 · Dec 31, 2025Inventory
40.49MUSDFY2025 · Dec 31, 2025Accounts Payable
2.91MUSDFY2025 · Dec 31, 2025Short-term Debt
14.20MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.99MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.89MUSDFY2025 · Dec 31, 2025Long-term Debt
350.51MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
197.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.56MUSDFY2025 · Dec 31, 2025Retained Earnings
10.12MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
372.71MUSDvs all stocks (USD)
52-Week Low
1.99USDUpdated Jul 19, 202652-Week High
7.25USDUpdated Jul 19, 202652-Week Change
204.20%vs all stocks
Beta
0.6500xvs all stocks
50-Day MA
5.25USDUpdated Jul 19, 2026200-Day MA
3.84USDUpdated Jul 19, 2026Avg 10-Day Volume
3.57MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.36MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.7100USDUpdated Jul 19, 2026Other Income / Expense
-90.89MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.51
Financial Health
Altman Z-Score 3.79: safe zoneNotable
Altman Z-Score: 3.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.67B, above the global median of $1.15BNotable
Market cap (USD): 2,670,650,105Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk